Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy

Akihiko Sawaki, MD, Kana Miyazaki, MD PhD, Toshifumi Takeuchi, MD PhD, Kyoko Kobayashi, MD PhD, Hiroshi Imai, MD PhD, Isao Tawara, MD PhD, Ryoichi Ono, MD PhD, Tetsuya Nosaka, MD PhD, Motoko Yamaguchi, MD PhD, Naoyuki Katayama, MD PhD

Blood (2019) 134 (Supplement_1): 1624.

https://doi.org/10.1182/blood-2019-122796

Published: 2019

Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 3963.

https://doi.org/10.1182/blood-2019-128580

Published: 2019

Journal Articles

Autonomous Ca 2+ Oscillations Reflect Oncogenic BCR-Signaling in Multiple B-Cell Malignancies and Are Essential for Survival and Proliferation

Kohei Kume, PhD, Liting Chen, PhD, Jae-Woong Lee, PhD, Markus Muschen, MD

Blood (2018) 132 (Supplement 1): 1373.

https://doi.org/10.1182/blood-2018-99-117315

Published: 2018

Journal Articles

Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia with High Tumor Burden Treated with BFM95-Based Protocol Combining Rituximab: A Report from Shanghai, China

Yang Fu, MBBS, Hongsheng Wang, MD, Xiaowen Zhai, MD PhD, Xiaowen Qian, MD, Jianhua Meng, MD, Hui Miao, MD, Xiaohua Zhu, MD PhD, Yi Yu, MD, Fengjuan Lu, MD

Blood (2017) 130 (Supplement 1): 4162.

https://doi.org/10.1182/blood.V130.Suppl_1.4162.4162

Published: 2017

Journal Articles

Incidence Patterns of Patients with Two or More Lymphoid Malignancies in a Patient with a Prior History of Lymphoid Malignancy: A Population-Based Cancer Registry Study in Nagasaki, Japan

Masako Iwanaga, MD PhD MPH, Daisuke Niino, MD PhD, Thi My Hanh Luong, Shiro Miura, Masahiro Nakashima

Blood (2017) 130 (Supplement 1): 4167.

https://doi.org/10.1182/blood.V130.Suppl_1.4167.4167

Published: 2017

Journal Articles

B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma

Blood (2017) 129 (3): 333–346.

https://doi.org/10.1182/blood-2016-05-718775

Published: 2017

Includes: Supplemental data

Journal Articles

Estimated Late Health Outcomes in Children Newly Diagnosed with Mature B-Cell Non-Hodgkin Lymphoma Treated with Contemporary LMB Chemotherapy Based upon Similarly Treated Participants in the Childhood Cancer Survivor Study (CCSS)

Matthew J. Ehrhardt, MD MS, Yan Chen, MMath, John Sandlund, MD, Elizabeth C. Bluhm, MD, Robert J. Hayashi, MD, Wendy M. Leisenring, ScD, Monika L. Metzger, MD, Kirsten K. Ness, PhD, Kevin R. Krull, PhD, Kevin C. Oeffinger, MD, Leslie L. Robison, PhD, Yutaka Yasui, PhD, Gregory T. Armstrong, MD MSCE, Melissa M. Hudson, MD, Daniel A. Mulrooney, MD

Blood (2016) 128 (22): 3609.

https://doi.org/10.1182/blood.V128.22.3609.3609

Published: 2016

Journal Articles

B-Cell Receptor Driven MALT1 Activity Regulates MYC Signaling in Mantle Cell Lymphoma

Blood (2016) 128 (22): 611.

https://doi.org/10.1182/blood.V128.22.611.611

Published: 2016

Journal Articles

The B-Cell Receptor of Primary Cutaneous Follicle Center Lymphoma: Implications for Pathogenesis

Marvyn T. Koning, BSc, Sander A.J. van der Zeeuw, BSc, Willem H. Zoutman, BSc, Maarten H. Vermeer, MD PhD, Rein Willemze, MD PhD, Hendrik Veelken, MD PhD, Cornelis P. Tensen, PhD

Blood (2016) 128 (22): 4136.

https://doi.org/10.1182/blood.V128.22.4136.4136

Published: 2016

Journal Articles

Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand

Blood (2015) 126 (23): 3326.

https://doi.org/10.1182/blood.V126.23.3326.3326

Published: 2015

Journal Articles

Rationale for targeting the pre–B-cell receptor signaling pathway in acute lymphoblastic leukemia

Markus Müschen

Blood (2015) 125 (24): 3688–3693.

https://doi.org/10.1182/blood-2015-01-567842

Published: 2015

Journal Articles

Obinutuzumab (GA101) Significantly Inhibits Cell Proliferation and Induces Programmed Cell Death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May be a Future Targeted Agent for the Treatment of PMBL

Changhong Yin, MS, Sanghoon Lee, PhD MSc., Timmy O'Connell, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2014) 124 (21): 4492.

https://doi.org/10.1182/blood.V124.21.4492.4492

Published: 2014

Journal Articles

Recurrent Mutations within the Nfkbie gene: A Novel Mechanism for NF-κB Deregulation in Aggressive Chronic Lymphocytic Leukemia

Blood (2014) 124 (21): 297.

https://doi.org/10.1182/blood.V124.21.297.297

Published: 2014

Journal Articles

Autologous and Allogeneic Transplantation for Pediatric Mature B-Cell Non-Hodgkin Lymphoma in Japan

Naoto Fujita, MD PhD, Ryoji Kobayashi, MD PhD, Yoshiko Atsuta, MDPhD, Tetsuo Mitsui, MD PhD, Fuminori Iwasaki, MD, Junji Suzumiya, MD PhD, Yoji Sasahara, MD PhD, Masami Inoue, MD, Katsuyoshi Koh, MD PhD, Hisashi Sakamaki, MDPhD, Hiromasa Yabe, MD PhD, Keisei Kawa, MD PhD, Koji Kato, MD, Ritsuro Suzuki, MD PhD

Blood (2014) 124 (21): 2540.

https://doi.org/10.1182/blood.V124.21.2540.2540

Published: 2014

Journal Articles

Differentiating Burkitt Lymphoma from Burkitt-like Lymphoma in Pediatrics: Report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study

Blood (2014) 124 (21): 1651.

https://doi.org/10.1182/blood.V124.21.1651.1651

Published: 2014

Journal Articles

Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing

Natalie Bell, PhD, Helen J Blair, PhD, Josef Vormoor, MD FRCPCH, Chris Bacon, MBChB, PhD, Vikki Rand, PhD, Olaf Heidenreich, PhD, Simon Bomken, PhD MBBS

Blood (2014) 124 (21): 5501.

https://doi.org/10.1182/blood.V124.21.5501.5501

Published: 2014

Journal Articles

Obinutuzumab (GA101), a Novel Type II Glycoengineered CD20 Antibody, Significantly Induced Programmed Cell Death In Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May Be a Future Potential Targeted Agent For The Treatment Of PMBL

Changhong Yin, MS, Timmy O'Connell, MS, Janet Ayello, MS, MT(ASCP), Carmella vande Ven, MA, Sanghoon Lee, PhD, MSc, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 5146.

https://doi.org/10.1182/blood.V122.21.5146.5146

Published: 2013

Journal Articles

Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL

Changhong Yin, MS, Tae-Hoon Chung, PhD, Janet Ayello, MS, MT(ASCP), Tae-Hyun Park, MS, Carmella van de Ven, MA, Mitchell S. Cairo, MD, Sanghoon Lee, Ph.D, MSc.

Blood (2013) 122 (21): 3852.

https://doi.org/10.1182/blood.V122.21.3852.3852

Published: 2013

Journal Articles

Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy

Mary Gerrard, Ian M. Waxman, Richard Sposto, Anne Auperin, Sherrie L. Perkins, Stanton Goldman, Lauren Harrison, Ross Pinkerton, Keith McCarthy, Martine Raphael, Catherine Patte, Mitchell S. Cairo

Blood (2013) 121 (2): 278–285.

https://doi.org/10.1182/blood-2012-04-422709

Published: 2013

Includes: Supplemental data

Journal Articles

Burkitt Lymphoma Specific Zinc Finger Protein ZNF385B Is Involved in Regulation of B Cell Apoptosis

Kazutoshi Iijima, PhD, Hiroyuki Yamada, MD, Masashi Miharu, MD, Atsuko Nakazawa, MD, PhD, Junichiro Fujimoto, MD, PhD, Kenichiro Kobayashi, MD, PhD, Hajime Okita, MD, PhD, Nobutaka Kiyokawa, MD, PhD

Blood (2011) 118 (21): 1584.

https://doi.org/10.1182/blood.V118.21.1584.1584

Published: 2011

NARROW

Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Autonomous Ca 2+ Oscillations Reflect Oncogenic BCR-Signaling in Multiple B-Cell Malignancies and Are Essential for Survival and Proliferation

Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia with High Tumor Burden Treated with BFM95-Based Protocol Combining Rituximab: A Report from Shanghai, China

Incidence Patterns of Patients with Two or More Lymphoid Malignancies in a Patient with a Prior History of Lymphoid Malignancy: A Population-Based Cancer Registry Study in Nagasaki, Japan

B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma

Estimated Late Health Outcomes in Children Newly Diagnosed with Mature B-Cell Non-Hodgkin Lymphoma Treated with Contemporary LMB Chemotherapy Based upon Similarly Treated Participants in the Childhood Cancer Survivor Study (CCSS)

B-Cell Receptor Driven MALT1 Activity Regulates MYC Signaling in Mantle Cell Lymphoma

The B-Cell Receptor of Primary Cutaneous Follicle Center Lymphoma: Implications for Pathogenesis

Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand

Rationale for targeting the pre–B-cell receptor signaling pathway in acute lymphoblastic leukemia

Obinutuzumab (GA101) Significantly Inhibits Cell Proliferation and Induces Programmed Cell Death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May be a Future Targeted Agent for the Treatment of PMBL

Recurrent Mutations within the Nfkbie gene: A Novel Mechanism for NF-κB Deregulation in Aggressive Chronic Lymphocytic Leukemia

Autologous and Allogeneic Transplantation for Pediatric Mature B-Cell Non-Hodgkin Lymphoma in Japan

Differentiating Burkitt Lymphoma from Burkitt-like Lymphoma in Pediatrics: Report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study

Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing

Obinutuzumab (GA101), a Novel Type II Glycoengineered CD20 Antibody, Significantly Induced Programmed Cell Death In Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May Be a Future Potential Targeted Agent For The Treatment Of PMBL

Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL

Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy

Burkitt Lymphoma Specific Zinc Finger Protein ZNF385B Is Involved in Regulation of B Cell Apoptosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only